Focused On-demand Library for Dynein regulatory complex protein 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q96MC2

UPID:
DRC1_HUMAN

ALTERNATIVE NAMES:
Coiled-coil domain-containing protein 164

ALTERNATIVE UPACC:
Q96MC2; A8K1N8; Q53R91; Q53TA3; Q8NDI5

BACKGROUND:
The Dynein regulatory complex protein 1, or Coiled-coil domain-containing protein 164, is essential for the proper function of motile cilia and flagella. It ensures the correct alignment and integrity of the distal axoneme and plays a key role in the assembly of the nexin-dynein regulatory complex (N-DRC). This protein's function is critical for the stabilization of inner dynein arms and radial spokes, facilitating effective ciliary and flagellar motility.

THERAPEUTIC SIGNIFICANCE:
The involvement of Dynein regulatory complex protein 1 in Primary Ciliary Dyskinesia and Spermatogenic Failure 80 underscores its potential as a target for therapeutic intervention. By elucidating the mechanisms by which this protein influences ciliary and flagellar motility, researchers can pave the way for novel treatments for these genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 1128 of 8789